lines of Polish Agency for Health Technology Assessment. RESULTS: As a result of a systematic search of publications, one single-blind, randomized clinical trial (Flowers 2008), fulfilling the predefined inclusion criteria, was found. The trial directly compared the clinical effectiveness of extracorporeal photopheresis combined with conventional therapy vs conventional therapy alone in the treatment of cutaneous cGvHD that could not be controlled by steroids. Moreover, there were identified 45 non-randomised, single-arm clinical trials which assessed the clinical effectiveness of ECP in analysed indications. Based on identified clinical trials it could be concluded that there is clinically relevant response to ECP treatment among patients with acute or chronic GvHD. The highest improvement was observed in skin, liver and gut among patients with aGvHD and in skin but also in mucosa, liver and lungs involvement among patients with cGvHD. Moreover, it was showed that ECP treatment is connected with reduction in the use of immunosuppressant (mainly steroids) in both groups of patients: with acute or chronic steroidrefractory or steroid-dependant GvHD. The reduction in steroid dose allows to reduces the risk of life-threatening bacterial, viral and fungal infections. ECP is very well tolerated procedure. Infrequent adverse events are usually mild and seldom led to discontinuation of the treatment. CONCLUSIONS: Results obtained from clinical trials included in the systematic review showed that there exists clinical benefit associated with the use of ECP in the treatment of pediatric and adult patients with steroid-refractory, steroid-dependant acute or chronic GvHD. liver cancer and was deemed not related to the device. Of 47 subjects with 53 device complication events at 1 year, 18 (1.6%) experienced an event at 3-months, 9 (0.8%) at 6-months, and 20 (1.8%) at 1-year. Subjects who reported device complications were port displacement (1.8%), pouch dilatation (0.8%), band erosion (0.5%), devicerelated infection (0.5%), band slippage (0.4%), port leak (0.1%), and both band slippage and pouch dilatation (0.3%). Eighteen (1.6%) subjects had explants and 3 (0.3%) had the LAGB surgically revised and replaced. The indications for explants included band erosion, band slippage, band intolerance, esophageal dilatation, pouch dilatation, device-related infection, abdominal pain, dysphagia, and small bowel obstruction. Minor device related revisions included access port revision 23(2.1%) and reposition of LAGB 4(0.4%). CONCLUSIONS: LAGB was associated with significant weight loss, with less than 2% of subjects undergoing explantation of the device within year 1 of this 5-year on-going study. Many reported device complications were considered to be non-serious and could be corrected in an outpatient setting. 
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PMD8 ONE YEAR EVALUATION OF EFFECTIVENESS AND DEVICE COMPLICATION OUTCOMES IN THE HELPING EVALUATE REDUCTION IN OBESITY (HERO) STUDY

MEDICAL DEVICE/DIAGNOSTICS -Cost Studies
PMD9 A COMPARATIVE ASSESSMENT OF COST IMPLICATIONS OF NOVEL DRUG VERSUS NOVEL DEVICE-BASED TREATMENTS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
OBJECTIVES:
After decades of warfarin as the dominant strategy for stroke prevention in atrial fibrillation (SPAF), new treatments are available. These include new pharmaceuticals like dabigatran etexilate and a device based approach, left atrial appendage closure (LAAC). Studies have compared the economics of pharmaceutical treatments, but the cost implications of the device-based approach with high initial procedural costs compared to these new drugs, with high annual costs for life, have not been demonstrated. This analysis compares overall costs of SPAF with LAAC to dabigatran 110mg twice daily. METHODS: An Excel-based cost impact model was developed using data from PROTECT-AF (Holmes 2009) and RE-LY clinical trial (Connelly 2009), both of which evaluated patients with a CHADS2 score Ͼ1. These studies reported similar rates of adverse events, with the exception of bleeding events which were more frequent in dabigatran patients. The model captures all costs associated with treatment, discontinuation of care and complications. Costs were based on the German system, using published DRGs and tariffs associated with procedures, drugs, and disability care. RESULTS: First year average per patient cost of LAAC was €11,076 compared to €3,251 for dabigatran. However, the overall cost of care at 5 years for LAAC (€13,547) was less than dabigatran (€13,675) due to higher annual drug and complication costs in the dabigatran arm. CONCLUSIONS: Although LAAC was higher cost than dabigatran in the first year, the total cost of care for dabigatran increased substantially each year, compared to only modest annual costs for LAAC past the first year. The full burden of costs associated with dabigatran is higher than with LAAC after five years and continues to accrue due to high regular annual costs. This is an important consideration for budget holders in evaluating lifetime treatment when many AF patients are now living into their eighties and beyond. 
PMD10 ANALYSIS OF COSTS OF COMPLICATIONS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS, COMPARING DOSE-ADJUSTED WARFARIN TO LEFT ATRIAL APPENDAGE CLOSURE
OBJECTIVES:
Major practice changes require both clinical and economic rationale, especially where a novel device replaces an established pharmaceutical therapy. Recent studies have reported the clinical benefits of percutaneous left atrial appendage closure (LAAC) for stroke prevention in atrial fibrillation (SPAF) as compared to standard warfarin anticoagulation, but the cost implications of the devicebased approach have not yet been demonstrated. This analysis highlights the ongoing costs of complications associated with a long standing pharmaceutical therapy compared to a device-based approach. METHODS: An Excel-based cost impact model was developed using data from the PROTECT-AF clinical trial which randomized 707 AF patients to either LAAC or warfarin (Holmes 2009). The model captured the costs of complications in AF, including strokes, systemic embolism, major extracranial bleeding and complications associated with the LAAC procedure. Costs for stroke included only the acute, direct costs and did not capture the long-term societal costs associated with disability. Germany, which recently recognized the LAAC procedure with a unique DRG code, was the basis for costs, using published DRGs and tariffs associated with procedures, drugs, and care. RESULTS: The high rate of adverse events in the warfarin arm generated €6,414 in medical costs for complications per patient at 5 years, compared to €3,276 for LAAC. These included mean costs of €3,239 for stroke and systemic embolism and €970 for major bleeding in the warfarin arm, compared to €1,551 and €484 respectively for LAAC. The mean annual cost of complications for warfarin was roughly twice that of LAAC, (€1,283 versus €655). CONCLUSIONS: The complication cost differential highlights the need for decision makers to consider the totality of long-term costs and clinical implications of lifetime treatment strategies for SPAF. 
PMD11 THE COST OF POOR SAMPLE QUALITY: ASSESSING THE FINANCIAL IMPACT OF SAMPLE REJECTION AND RECOLLECTION IN HEALTH CARE INSITUTIONS
OBJECTIVES:
To model the financial impact for the health care institution of specimen rejection due to preanalytical errors in the laboratory testing phase, using institution specific data. METHODS: Critical data such as number of beds; overall budget; number of patients of different types seen each year; and number of sample rejections, as well as qualitative data, eg. probable impact of sample rejection were collected by interviewing institution staff from multiple country institutions (Nϭ10). The data were then entered into a model to calculate the possible financial impact of laboratory sample rejections. The model separates patients into different groups according to the likely effects of having a sample rejected, the probability that the rejection would have a low, medium or high impact and the consequences on institution time and resources. The overall consequence, or opportunity cost, was expressed as patient treatment time and financial cost. RESULTS: The size of the institutions ranged from 326 to 1,200 beds, with total operating costs varying between €41 million and €1.1 billion. The number of blood tests per month was between 37,000 and 458,000 and of these between 0.09% and 2% were rejected (mean 0.93%). The total cost of specimen rejection ranged from €22k to €5.9 million per annum (mean €1.9 million), equating to a percentage of total operating costs from 0.1% to 1.2% (mean 0.4%). The estimated cost per patient for a sample rejection was from €29 to €349 (mean €171). CONCLUSIONS: A customisable model allows institutions to estimate, using local data and assumptions, the effect of sample rejection on patient treatment and cost. Results can be compared to those from other institutions to benchmark performance and assumptions. The results demonstrated that a reduction in the number of rejected samples due to preanalytical errors could lead to significant cost savings for most institutions. Becton, Dickinson SA, Madrid, Madrid, Spain, 4 Becton, Dickinson Benelux NV, Erembodegem, Aalst, Belgium OBJECTIVES: Needlestick injuries (NSIs) represent a significant clinical and economic burden to health care systems and society. The EU Directive on the prevention of sharps injuries recommends adherence to a range of safety measures, of which providing safety-engineered devices (SEDs) forms a key part. An economic model was constructed to investigate the potential hospital budget savings associated with the use of SEDs rather than conventional (i.e. non-safety-engineered) devices when conducting procedures with sharp devices. METHODS: An incidence-based, deterministic budget impact model with a five-year time horizon was A346 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
PMD12 A BUDGET IMPACT MODEL TO INVESTIGATE POTENTIAL COST SAVINGS ASSOCIATED WITH THE USE OF SAFETY-ENGINEERED SHARP DEVICES IN BELGIUM
